| Bioactivity | Framycetin (Neomycin B), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a Ki of 35 μM. Framycetin competes for specific divalent metal ion binding sites in RNase P RNA. Framycetin inhibits hammerhead ribozyme with a Ki of 13.5 μM. Framycetin, a 5″-azido neomycin B precursor, binds the Drosha site in miR-525 and is used for hepatic encephalopathy and enteropathogenic E. coli infections[1][2]. |
| Invitro | The inhibition of RNase P RNA cleavage by Framycetin (Neomycin B; Fradiomycin B) is sensitive to pH and an increase in pH suppresses the inhibition in other systems[1]. Framycetin targets the bacterial and human ribosome and affect translation. 5″-azido neomycin B and Framycetin selectively inhibit production of the mature miRNA, boosts a downstream protein, and inhibits invasion in HCC cell line[2]. Framycetin binds to a structural rather than a sequence motif of the RNA. Its primary cognate target is the decoding site of the 16S rRNA, but it also binds to the Rev-responsive element in HIV-1, group I introns, and the hammerhead ribozyme, and thus inhibits their biological function[3]. Framycetin induces misreading of the genetic code during translation and inhibits several ribozymes. The ribosomal target site is the 16 S rRNA 1400 to 1500 region[4]. |
| Name | Framycetin |
| CAS | 119-04-0 |
| Formula | C23H46N6O13 |
| Molar Mass | 614.64 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Solution, -20°C, 2 years |